STOCK TITAN

ADMA Biologics director Guiheen sells 10,000 shares

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

ADMA Biologics director Lawrence P. Guiheen exercised options covering 10,000 shares at $5 per share on November 16, 2026, and sold 10,000 shares of common stock at $13.92 per share that day. As of the transaction date, his reported holdings included 58,254 shares and 5,345 unvested restricted stock units.

The option was exercised partly because of its near-term expiration. No Rule 10b5-1 plan is reported.

Insider Guiheen Lawrence P.
Role Director
Sold 10,000 shs ($139K)
Approx. gross sale proceeds $139K
Approx. exercise cost $50K
Approx. pre-tax spread $89K
Type Security Shares Price Value
Exercise Stock Option (Right to Buy) F5, F6 10,000 $0.00 $0.00
Exercise Common Stock 10,000 $5.00 $50K
Sale Common Stock F1, F2 10,000 $13.92 $139K
Holding Common Stock F3 -- -- --
Holding Common Stock F4 -- -- --
Holdings After Transaction: Stock Option (Right to Buy) — 0 options (Direct); Common Stock — 63,599 shares (Direct); Common Stock — 122,911 shares (Indirect, See Footnote)
Footnotes (6)
  1. F1. The price reported in Column 4 is the price at which the shares were sold.
  2. F2. Includes, as of the transaction date, (i) 5,345 unvested restricted stock units ("RSUs") granted on February 9, 2026, which will fully vest on February 9, 2027, subject to the Reporting Person's continued service as of such vesting date and that will be settled into common stock upon vesting; and (ii) 58,254 shares of common stock owned by the Reporting Person. Each RSU represents a contingent right to receive one share of common stock of the Issuer.
  3. F3. These shares are held in the Lawrence P Guiheen Revocable Trust DTD 9/20/19, over which the Reporting Person retains control.
  4. F4. These shares are held in the Lawrence P Guiheen Irrevocable Trust DTD 9/20/19, Arlene Guiheen TTEE, Katherine M Guiheen TTEE ("Guiheen Irrevocable Trust"), over which the Reporting Person retains control. The Reporting Person disclaims beneficial ownership of the securities held by the Guiheen Irrevocable Trust, except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.
  5. F5. The option was granted on February 14, 2017 and vested in twenty-four equal monthly installments, becoming fully vested on February 14, 2019.
  6. F6. The option terminates on the earlier of (i) February 14, 2027 and (ii) the one-year anniversary of the Reporting Person's ceasing to serve as a director of the Issuer. The Reporting Person is exercising this option due, in part, to its near-term expiration date.
Shares covered by options exercised 10,000 shares November 16, 2026
Exercise price $5 per share Options exercised November 16, 2026
Shares sold 10,000 shares November 16, 2026
Sale price $13.92 per share Common stock sold November 16, 2026
Common stock held 58,254 shares Reported as of November 16, 2026
Unvested restricted stock units 5,345 RSUs Reported as of November 16, 2026; subject to continued service through vesting
Option expiration February 14, 2027 The option terminates earlier if the director ceases to serve, under the stated terms
restricted stock units financial
"5,345 unvested restricted stock units"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
contingent right financial
"Each RSU represents a contingent right to receive one share"
vested financial
"becoming fully vested on February 14, 2019"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many ADMA shares did director Lawrence P. Guiheen sell?

Lawrence P. Guiheen sold 10,000 shares of ADMA common stock at $13.92 per share on November 16, 2026. On the same date, he exercised options covering 10,000 shares at a $5 per-share exercise price.

Why did ADMA director Lawrence P. Guiheen exercise his options?

The option was exercised in part because of its near-term expiration. It was granted February 14, 2017, vested in 24 equal monthly installments, and became fully vested February 14, 2019. It terminates on the earlier of February 14, 2027, or the one-year anniversary of his ceasing to serve as a director.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Guiheen Lawrence P.

(Last)(First)(Middle)
C/O ADMA BIOLOGICS, INC.
465 STATE ROUTE 17

(Street)
RAMSEY NEW JERSEY 07446

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
ADMA BIOLOGICS, INC. [ ADMA ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/16/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock11/16/2026M10,000A$573,599D
Common Stock11/16/2026S10,000D$13.92(1)63,599(2)D
Common Stock71,921ISee Footnote(3)
Common Stock50,990ISee Footnote(4)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$511/16/2026M10,000 (5)02/14/2027(6)Common Stock10,000$00D
Explanation of Responses:
1. The price reported in Column 4 is the price at which the shares were sold.
2. Includes, as of the transaction date, (i) 5,345 unvested restricted stock units ("RSUs") granted on February 9, 2026, which will fully vest on February 9, 2027, subject to the Reporting Person's continued service as of such vesting date and that will be settled into common stock upon vesting; and (ii) 58,254 shares of common stock owned by the Reporting Person. Each RSU represents a contingent right to receive one share of common stock of the Issuer.
3. These shares are held in the Lawrence P Guiheen Revocable Trust DTD 9/20/19, over which the Reporting Person retains control.
4. These shares are held in the Lawrence P Guiheen Irrevocable Trust DTD 9/20/19, Arlene Guiheen TTEE, Katherine M Guiheen TTEE ("Guiheen Irrevocable Trust"), over which the Reporting Person retains control. The Reporting Person disclaims beneficial ownership of the securities held by the Guiheen Irrevocable Trust, except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.
5. The option was granted on February 14, 2017 and vested in twenty-four equal monthly installments, becoming fully vested on February 14, 2019.
6. The option terminates on the earlier of (i) February 14, 2027 and (ii) the one-year anniversary of the Reporting Person's ceasing to serve as a director of the Issuer. The Reporting Person is exercising this option due, in part, to its near-term expiration date.
/s/ Lawrence P. Guiheen, by Michael A. Goldstein as Attorney-in-fact11/16/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading